🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

India set to ship drug sought by Trump for coronavirus

Published 10-04-2020, 05:47 pm
Updated 10-04-2020, 05:48 pm
TEVA
-
ZYDU
-
IPCA
-

By Zeba Siddiqui and Sumit Khanna

NEW DELHI/AHMEDABAD, April 10 (Reuters) - India is set to begin shipping the malaria drug hydroxychloroquine to the United States where President Donald Trump has touted it as a potential weapon against the coronavirus.

"The first shipments should start next week," said Sudarshan Jain, secretary general of Indian Pharmaceutical Alliance (IPA).

India is the world's largest producer of hydroxychloroquine but last month banned most exports to secure its own supplies, drawing warnings of retaliation from Trump.

This week India allowed some exports of the drug and Trump has thanked New Delhi for the decision. said companies in India are ramping up capacity to meet the U.S. demand, including Teva Pharmaceutical Industries TEVA.TA , IPCA Laboratories IPCA.NS and Cadila Healthcare CADI.NS .

Cadila has increased production tenfold to 30 metric tonnes per month and is ready to produce more if needed, Managing Director Sharvil Patel told Reuters.

Companies are ramping up while battling a three-week nationwide lockdown India imposed on March 25.

Cadila is based in western India's Gujarat state, a drug production hub where industry insiders say the shutdown has forced companies to contend with supply chain disruptions and worker shortages.

"There are 28 manufacturers of hydroxychloroquine in Gujarat," said H.G. Koshia, a senior drugs department official. "All of them have enhanced production in view of rise in demand."

The IPA's Jain said firms were confident they could produce adequate quantities to meet both global and domestic demand.

"The government is getting a lot of requests from other countries," Jain noted.

India is stocking at least four months' supply and has agreed to export to at least 30 countries, according to export body Pharmexcil's estimates.

Hydroxychloroquine is unproven as a treatment https://in.reuters.com/article/uk-health-coronavirus-usa-hydroxychloroq/special-report-doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-idINKBN21O2VH but its use has soared as the United States has quickly become the epicentre of the pandemic.

U.S. deaths due to coronavirus topped 16,400, while India's death toll stands at 199. https://in.reuters.com/article/health-coronavirus-southasia/south-asian-nations-weigh-tighter-lockdowns-as-coronavirus-cases-hit-12000-idINKCN21S0PK (Additonal reporting by Neha Dasgupta in New Delhi; writing by Abhirup Roy and Zeba Siddiqui; editing by Aditya Kalra and Jason Neely)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.